Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia.
Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.
Go deeper with GlobalData
The company is a specialised pharmaceutical wholesaler and holds a licence, issued by the country’s ministry of health, to import non-registered pharmaceutical products, orphan drugs and other life-saving medicines.
It sources a wide range of branded or generic equivalent drugs from across the globe to meet the needs of the local market.
Lotus Pharmaceuticals CEO Petar Vazharov stated: “We are delighted at our new collaboration with Teraju.
“This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and a rich pipeline of products.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company confirmed that the alliance is in line with its strategic plan to expand in Southeast Asia.
The collaboration will launch a portfolio of products in the therapeutic categories of ophthalmology, cardio-metabolic and oncology, commencing in the fourth quarter of 2023.
Lotus Pharmaceuticals, Alvogen and NRx Pharmaceuticals recently signed a global collaboration agreement for the development and commercialisation of NRX-101 to treat suicidal treatment-resistant bipolar depression (S-TRBD).
The company will buy worldwide rights for the therapy and handle its commercialisation activities in markets outside the US.
